Find Udenafil manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

VMF

NDC API

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as:
Molecular Formula
C25H36N6O4S
Molecular Weight
516.7  g/mol
InChI Key
IYFNEFQTYQPVOC-UHFFFAOYSA-N

Udenafil
1 2D Structure

Udenafil

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
3-(1-methyl-7-oxo-3-propyl-4H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzenesulfonamide
2.1.2 InChI
InChI=1S/C25H36N6O4S/c1-5-8-20-22-23(31(4)29-20)25(32)28-24(27-22)19-16-18(10-11-21(19)35-15-6-2)36(33,34)26-13-12-17-9-7-14-30(17)3/h10-11,16-17,26H,5-9,12-15H2,1-4H3,(H,27,28,32)
2.1.3 InChI Key
IYFNEFQTYQPVOC-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CCCC1=NN(C2=C1NC(=NC2=O)C3=C(C=CC(=C3)S(=O)(=O)NCCC4CCCN4C)OCCC)C
2.1.5 Isomeric SMILES
CCCC1=NN(C2=C1NC(=NC2=O)C3=C(C=CC(=C3)S(=O)(=O)NCCC4CCCN4C)OCCC)C
2.2 Create Date
2006-07-28
3 Chemical and Physical Properties
Molecular Weight 516.7 g/mol
Molecular Formula C25H36N6O4S
XLogP33
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count7
Rotatable Bond Count11
Exact Mass516.25187482 g/mol
Monoisotopic Mass516.25187482 g/mol
Topological Polar Surface Area126 A^2
Heavy Atom Count36
Formal Charge0
Complexity894
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count1
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Drugs in Development

read-more
read-more

Details:

The proceeds will be used to support the ongoing global Phase 3 FUEL-2 trial of MZ101 (udenafil) for patients with Fontan circulation.


Lead Product(s): Udenafil,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Midas-Meritz

Deal Size: $20.0 million Upfront Cash: Undisclosed

Deal Type: Financing June 13, 2025

blank

01

Mezzion Pharma Co Ltd

South Korea
arrow
BioJapan
Not Confirmed

Mezzion Pharma Co Ltd

South Korea
arrow
BioJapan
Not Confirmed

Details : The proceeds will be used to support the ongoing global Phase 3 FUEL-2 trial of MZ101 (udenafil) for patients with Fontan circulation.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Undisclosed

June 13, 2025

blank
  • Development Update

Details:

Udenafil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Defects, Congenital.


Lead Product(s): Udenafil,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 26, 2023

blank

02

Mezzion Pharma

Country
arrow
BioJapan
Not Confirmed

Mezzion Pharma

Country
arrow
BioJapan
Not Confirmed

Details : Udenafil is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Heart Defects, Congenital.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 26, 2023

blank

Details:

The financing will fund FUEL-2, Mezzion's confirmatory phase 3 trial, along with future commercialization and regulatory submissions in other countries including Europe. Mezzion is looking to market JURVIGO® (udenafil), a highly selective, unique and potent PDE-5 inhibitor.


Lead Product(s): Udenafil,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jurvigo

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: BRV Capital Management

Deal Size: $40.0 million Upfront Cash: Undisclosed

Deal Type: Financing April 25, 2023

blank

03

Mezzion Pharma Co Ltd

South Korea
arrow
BioJapan
Not Confirmed

Mezzion Pharma Co Ltd

South Korea
arrow
BioJapan
Not Confirmed

Details : The financing will fund FUEL-2, Mezzion's confirmatory phase 3 trial, along with future commercialization and regulatory submissions in other countries including Europe. Mezzion is looking to market JURVIGO® (udenafil), a highly selective, unique and po...

Product Name : Jurvigo

Product Type : Miscellaneous

Upfront Cash : Undisclosed

April 25, 2023

blank

Details:

MZ101 (udenafil) is a phosphodiesterase type 5 inhibitor, improves measures of exercise performance at the ventilatory anaerobic threshold in individuals with fontan physiology.


Lead Product(s): Udenafil,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jurvigo

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 21, 2023

blank

04

Mezzion Pharma Co Ltd

South Korea
arrow
BioJapan
Not Confirmed

Mezzion Pharma Co Ltd

South Korea
arrow
BioJapan
Not Confirmed

Details : MZ101 (udenafil) is a phosphodiesterase type 5 inhibitor, improves measures of exercise performance at the ventilatory anaerobic threshold in individuals with fontan physiology.

Product Name : Jurvigo

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 21, 2023

blank

Details:

Mezzion sought clarity on the critical elements of an additional clinical trial that may be needed to complete the NDA submission for Udenafil for Single Ventricle Heart Disease.


Lead Product(s): Udenafil,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jurvigo

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 31, 2022

blank

05

Mezzion Pharma Co Ltd

South Korea
arrow
BioJapan
Not Confirmed

Mezzion Pharma Co Ltd

South Korea
arrow
BioJapan
Not Confirmed

Details : Mezzion sought clarity on the critical elements of an additional clinical trial that may be needed to complete the NDA submission for Udenafil for Single Ventricle Heart Disease.

Product Name : Jurvigo

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 31, 2022

blank

Details:

The FDA had previously granted Mezzion's request to designate udenafil for treatment of single ventricle congenital heart disease as a drug for a Rare Pediatric Disease.


Lead Product(s): Udenafil,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jurvigo

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 25, 2021

blank

06

Mezzion Pharma Co Ltd

South Korea
arrow
BioJapan
Not Confirmed

Mezzion Pharma Co Ltd

South Korea
arrow
BioJapan
Not Confirmed

Details : The FDA had previously granted Mezzion's request to designate udenafil for treatment of single ventricle congenital heart disease as a drug for a Rare Pediatric Disease.

Product Name : Jurvigo

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 25, 2021

blank

Details:

The NDA submission, which totals nearly 100,000 pages, is supported by data from more than 700 documents including more than 200 studies that Mezzion has completed during the last 2 decades since its founding in 2002.


Lead Product(s): Udenafil,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jurvigo

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 30, 2020

blank

07

Mezzion Pharma Co Ltd

South Korea
arrow
BioJapan
Not Confirmed

Mezzion Pharma Co Ltd

South Korea
arrow
BioJapan
Not Confirmed

Details : The NDA submission, which totals nearly 100,000 pages, is supported by data from more than 700 documents including more than 200 studies that Mezzion has completed during the last 2 decades since its founding in 2002.

Product Name : Jurvigo

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 30, 2020

blank

Details:

Subjects on udenafil therapy showed a statistically significant improvement in ventricular performance as measured by MPI as compared to subjects taking placebo over the same time period.


Lead Product(s): Udenafil,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Jurvigo

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 18, 2020

blank

08

Mezzion Pharma Co Ltd

South Korea
arrow
BioJapan
Not Confirmed

Mezzion Pharma Co Ltd

South Korea
arrow
BioJapan
Not Confirmed

Details : Subjects on udenafil therapy showed a statistically significant improvement in ventricular performance as measured by MPI as compared to subjects taking placebo over the same time period.

Product Name : Jurvigo

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 18, 2020

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

BioJapan
Not Confirmed
arrow
arrow
BioJapan
Not Confirmed

Udenafil

Brand Name :

Dosage Form : Tablet

Dosage Strength : 200MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

BioJapan
Not Confirmed
arrow
arrow
BioJapan
Not Confirmed

Udenafil

Brand Name :

Dosage Form : Tablet

Dosage Strength : 200MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : India

blank

01

BioJapan
Not Confirmed
arrow
arrow
BioJapan
Not Confirmed

Udenafil

Dosage : Tablet

Dosage Strength : 200MG

Brand Name :

Approval Date :

Application Number :

Registration Country : India

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Looking for / Udenafil API manufacturers, exporters & distributors?

Udenafil manufacturers, exporters & distributors 1

68

PharmaCompass offers a list of Udenafil API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Udenafil manufacturer or Udenafil supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Udenafil manufacturer or Udenafil supplier.

PharmaCompass also assists you with knowing the Udenafil API Price utilized in the formulation of products. Udenafil API Price is not always fixed or binding as the Udenafil Price is obtained through a variety of data sources. The Udenafil Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Udenafil

Udenafil Manufacturers

A Udenafil manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Udenafil, including repackagers and relabelers. The FDA regulates Udenafil manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Udenafil API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Udenafil manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Udenafil Suppliers

A Udenafil supplier is an individual or a company that provides Udenafil active pharmaceutical ingredient (API) or Udenafil finished formulations upon request. The Udenafil suppliers may include Udenafil API manufacturers, exporters, distributors and traders.

click here to find a list of Udenafil suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Udenafil KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Udenafil Drug Master File in Korea (Udenafil KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Udenafil. The MFDS reviews the Udenafil KDMF as part of the drug registration process and uses the information provided in the Udenafil KDMF to evaluate the safety and efficacy of the drug.

After submitting a Udenafil KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Udenafil API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Udenafil suppliers with KDMF on PharmaCompass.

Udenafil NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Udenafil as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Udenafil API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Udenafil as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Udenafil and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Udenafil NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Udenafil suppliers with NDC on PharmaCompass.

Udenafil GMP

Udenafil Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Udenafil GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Udenafil GMP manufacturer or Udenafil GMP API supplier for your needs.

Udenafil CoA

A Udenafil CoA (Certificate of Analysis) is a formal document that attests to Udenafil's compliance with Udenafil specifications and serves as a tool for batch-level quality control.

Udenafil CoA mostly includes findings from lab analyses of a specific batch. For each Udenafil CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Udenafil may be tested according to a variety of international standards, such as European Pharmacopoeia (Udenafil EP), Udenafil JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Udenafil USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty